Houston AI data firm partners on Alzheimer’s clinical trial

now testing

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time. Photo omniscience.bio

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.”

The ADO2 trial will investigate INmune Bio's clinical-stage biotechnology XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation, according to its website. Its products are focused on "restoring function in the body's innate immune system to fight disease."

The trial is overenrolled with 208 patients diagnosed with mild Alzheimer’s disease or mild cognitive impairment. The top-line results are expected to be released in Q2 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” Tara Lehner, INmune Bio’s vice president of clinical operations, says in the statement. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.”

INmune will be able to use OmniScience's Vivo product to unify data from electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, labs, wearables, safety databases and more, according to the statement. The product has been shown to improve data quality and visualizations and reduce the reliance on spreadsheet-based data analysis during clinical trials.

Omniscience was originally founded in 2017, then known as Mercury Data Science. It rebranded and changed its name earlier this year. Holmes was named CEO in 2022.

Omniscience's Vivo product recently won first place in the CNS Summit 2024 Innovation Showcase in Boston and the Blue Whale Ribbon at the inaugural Whale Tank pitch competition during the 2024 Innovation Network Gathering (ING) in West Chester, Pennsylvania.

From Your Site Articles
Coya Therapeutics is looking into how a trendy weight loss drug could complement its Alzheimer’s disease treatment. Photo via Getty Images

Houston therapeutics innovator looks into GLP-1 drugs for Alzheimer’s treatment

drug discovery

Glucagon-like peptide 1, or GLP-1, agonists are all the rage right now thanks to drugs like Ozempic and Wegovy. Though they’re currently being prescribed for diabetes and weight loss, a Houston company reports that it may have found another use for GLP-1s.

Coya Therapeutics, a publicly traded clinical-stage biotechnology company, has filed intellectual property protection for a combination of its proprietary COYA 301 and GLP-1. Coya’s team believes that combining COYA 301, a low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs), with GLP-1 could be a game-changer in the fight against Alzheimer’s disease.

How does GLP-1 amplify the positive results already noted for COYA 301? The company will soon release phase 2 data for IL-2 in patients with Alzheimer's. Through distinct mechanisms, the pair of drugs could synergistically combat inflammation. That means that neurodegenerative maladies such as Alzheimer’s are just the beginning. The drug combination could also fight autoimmune and metabolic conditions. This isn’t the first combination therapy for Coya — Coya 302 is a pairing of LD IL-2 and CTLA-4 Ig that has also racked up some success in human trials.

According to Coya’s CEO, Howard Berman, “We believe that combination immunotherapy approaches will evolve to play a meaningful role in treating complex immune-based diseases that are driven by a host of pathophysiologic mechanisms.”

He goes on to add that the company has already had success with targeting “multiple, independent, and non-overlapping immune pathways simultaneously” with COYA 302, a combination of COYA 301 and CTLA-4 Ig, commercially known as Abatacept. That pairing is currently being evaluated in numerous neurodegenerative disease models, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, and Parkinson’s diseases.

“We will continue to expand our portfolio with additional synergistic drug combinations with COYA 301,” Berman adds.

The Belfer family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium. Photo via mdanderson.org

$20M donation drives neurodegeneration research in Houston

big impact

Neurodegeneration is one of the cruelest ways to age, but one recent donation is invigorating research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

Houston Methodist's Nantz National Alzheimer Center received a $1 million donation to continue research in neurodegenerative diseases. Photo via Houston Methodist

Houston hospital snags $1M to advance Alzheimer’s research

money moves

Thanks to a recent donation, Houston Methodist is setting up an endowment to support research in neurodegenerative diseases.

Susan and William “Dub” Henning, Jr. have committed to a $1 million gift to Houston Methodist to support Alzheimer’s research at the Nantz National Alzheimer Center at the hospital. This gift will be used to create the Susan and William Henning Jr. Neurodegenerative Research Endowment and in response, a NNAC family room will be named in memory of Dub’s parents, Lena and William Henning.

“Knowing the impact that Alzheimer’s can have not only on patients, but also on the immediate and extended family members experiencing the disease inspired us to support the work being done at the Nantz National Alzheimer Center,” says Dub Henning in a news release. “We want to give hope to families struggling with this disease and contribute to ultimately finding a cure.”

Every year, the NNAC — led by Joseph C. Masdeu — treats thousands of patients looking to prevent Alzheimer’s disease, slow memory loss progression, and improve their quality of life. In 2021 alone, the center provided more than 4,000 patient visits. The fresh funding will allow for Dr. Masdeu's research projects — including more than 26 current studies, 14 in clinical trials and 12 studies to clarify the nature of diseases causing dementia — to continue the important work.

“One of our clinical trials will determine the effects of exercise in preventing deposits of amyloid and tau, two of the proteins that accumulate in the brain of people living with Alzheimer’s disease, and we’re also exploring the role of proper sleep in disease development,” says Masdeu in the release. “Among other studies, we are collaborating with Baylor College of Medicine to define genetic and chemical factors predisposing to the accumulation of amyloid and tau in the brain of people at all stages of the Alzheimer’s spectrum.

"These promising developments would not be possible without the compassion and generosity of community supporters like the Henning family," he continues.

Susan and William “Dub” Henning, Jr. gave a $1 million gift to Houston Methodist. Photo courtesy of Houston Methodist

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas voters OK $3 billion for new dementia research institute

state funding

Texas voters on Nov. 4 overwhelmingly approved a ballot measure that provides $3 billion in state funding over a 10-year span for the newly established Dementia Prevention and Research Institute of Texas (DPRIT).

Thanks to the passage of Proposition 14, Texas now boasts the country’s largest state-funded initiative dedicated to dementia research and prevention, according to the Alzheimer’s Association. Up to $300 million in grants will be awarded during the 10-year funding period.

“This is a transformative moment for Texas and for the fight against Alzheimer’s and all other dementia,” said Joanne Pike, president and CEO of the Alzheimer’s Association. “Texans have chosen to invest in hope, innovation, and solutions for the millions of families affected by these devastating diseases. With the passage of Proposition 14, Texas is now poised to lead the nation in dementia research and prevention.”

The association says DPRIT will drive scientific breakthroughs, attract top-notch dementia researchers to Texas, and generate thousands of jobs statewide.

An estimated 460,000 Texans are living with dementia, the association says, and more than one million caregivers support them.

DPRIT is modeled after the Cancer Prevention and Research Institute of Texas (CPRIT). Since 2008, the state agency has awarded nearly $4 billion in grants to research organizations for cancer-related academic research, prevention programs, and product development.

An analysis by the McKinsey Health Institute found that investing in brain health initiatives like DPRIT could boost Texas’ GDP by $260 billion. Much of that GDP bump could benefit the Houston area, which is home to dementia-focused organizations such as UTHealth Houston Neurosciences, Baylor College of Medicine’s Center for Alzheimer’s and Neurodegenerative Diseases, the University of Texas Medical Branch at Galveston’s Collaborative Alzheimer’s Disease and Memory Disorders Program, and the Houston Methodist Research Institute’s John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory.

The Greater Houston Partnership says DPRIT holds the potential “to elevate Texas — particularly Houston — as a hub for brain health research.”

State Sen. Joan Huffman, a Houston Republican, is one of DPRIT’s champions. She sponsored legislation this year to create the institute and ask Texas voters to approve the $3 billion in funding.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said in May. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our health care community.”

Get your tickets to the 2025 Houston Innovation Awards today

Ticket Time

We're just one week away from the 2025 Houston Innovation Awards, and it's time to secure your seat for the annual event.

Join us on Nov. 13 at Greentown Labs for an intimate evening of networking and celebrating Houston's extensive innovation community. We'll honor the trailblazers and visionaries who are shaping the future of our city, and you'll connect with like-minded individuals, industry leaders, investors, and entrepreneurs.

From burgeoning startups to fast-growing scaleups, we'll celebrate outstanding nominees across 10 prestigious categories and unveil this year's winners during our live awards ceremony. Be in the room to see who is named 2025 Startup of the Year, 2025 Mentor of the Year, and more.

Individual tickets are available for $45 and include complimentary light bites, drinks, and non-reserved seating. A limited number of Founder Tickets are available for startup founders at a special discounted price of $35.

Bringing a group? Corporate 10-packs include light bites and drinks, as well as a full row of reserved seating for 10 guests, complete with company branding.

The event is just a week away, so secure your seats today. Then, get to know the finalists in each category via our editorial spotlights.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

Houston Innovation Awards to honor Wade Pinder as 2025 Trailblazer

And the award goes to...

On Nov. 13, we'll gather for the 2025 Houston Innovation Awards to celebrate the best and brightest in Houston innovation right now. And, as is tradition with the annual program, we'll honor one longstanding Houston innovator with the Trailblazer Award.

The award was established to recognize an individual who has left a profound impact on Houston's business and innovation ecosystem and is dedicated to continuing to support Houston and its entrepreneurs. The recipient is selected by our esteemed panel of judges from a pool of internal and external recommendations.

The 2025 Trailblazer Award recipient is Wade Pinder of Product Houston. A familiar face to those active in Houston's innovation sector, Pinder identifies as an "Ecosystem Wayseeker" and is the founder of Product Houston.

Pinder, a former product manager at Blinds.com, arrived in Houston in 2008 and has been deeply engaged in Houston’s startup and innovation scene since 2012. Over the years, he has supported hundreds of founders, product leaders, and community builders across the Houston area.

In 2023, he was honored as Mentor of the Year in the Houston Innovation Awards. Today, he fosters collaboration, clarity, and connection through his work at Product Houston, and he helps innovators find their place in the local sector via his monthly "Houston Ecosystem Mapping" sessions.

Read below for Pinder's insightful takes on the Houston innovation scene and what it means to blaze a new trail. Then, join us as we celebrate Pinder and all of our nominees and winners at the 2025 Houston Innovation Awards on Nov. 13 at Greentown Labs. Tickets are available now.

InnovationMap: Describe the growth of the Houston innovation ecosystem from your arrival in 2008 to now.

Wade Pinder: When I first arrived in Houston in 2008, the innovation ecosystem was more fragmented than it is today. Connecting with other innovators often meant attending a lot of hit-or-miss events. Over the years, it’s been incredible to see the network take shape and grow into a true community. I’ve had the privilege of being involved with several coworking spaces and accelerator programs along the way, and it’s been especially exciting to see Station Houston evolve into what is now the Ion District. What makes the Ion unique is how it blends openness and opportunity… ideas spill into and out of the space, and anyone can walk in, participate in programming, and find themselves in proximity to people who might help them take the next steps.

Additionally, the expansion of spaces like Texas Medical Center Innovation, Helix Park, The Cannon, and many others, have broadened Houston’s innovation landscape in powerful ways.

Today, when someone new moves to Houston and wants to plug into the startup and innovation scene, it’s much easier for them to find their way than when I moved here in 2008. I think that’s something Houston can really be proud of.

IM: As someone who engages with the broader Houston innovation community on a regular basis, what are the shared characteristics and traits that you see among its members?

WP: One of the things that makes Houston’s innovation community unique is how deeply it’s rooted in industry. So many of the innovators I meet come from within Houston’s major sectors, and they’ve seen firsthand where opportunities lie, which gives their innovation a certain practicality. They’re developing solutions that solve real, often complex, business and industry problems, not chasing trends or trying to create the next flashy consumer app.

What I admire most is that this community is growing in its understanding of the value of collaboration. They work with the systems and expertise that already exist, and find better ways to make them work together. Another shared trait I see across Houston’s innovators is a deep sense of curiosity and a drive to question the status quo while looking for better ways to build, improve, and solve.

IM: You’ve said, "Houston has Houston problems, and Houston needs Houston solutions." How do you see this taking shape in the innovation sector right now?

WP: When I first started getting connected to Houston’s startup and innovation scene in 2012, I noticed folks had a tendency to look at other cities and ask, "How can we do what they did?" Back then, we saw phrases like "Silicon Bayou" pop up, and while that enthusiasm was hopeful, it often discounted the things that make Houston unique. Over time, I’ve come to believe that the better question is: "What are we already great at, and how can we innovate from there?" The flip side of that question is to reflect on the things that hold us back as an ecosystem… identifying the friction points and finding practical ways to smooth them out.

From my time wandering around our ecosystem, I’ve come to understand Houston is great at infrastructure at scale, solving life-and-death challenges in the global spotlight, and "boldly going where no one’s gone before." These three things, in my opinion, capture the essence of Houston does best: We do hard things here.

What excites me today is that we’re applying innovation to those core strengths in ways that feel authentically Houston. One area I’m especially excited about is the emergence of the “New Space Economy,” captured beautifully in Wogbe Ofori’s thought piece “The Astropreneur’s Startup Journey Map.” It's a great example of how the next wave of space-related innovation might connect to Houston’s long-standing strengths in manufacturing, logistics, and problem-solving at scale.

Another challenge Houston faces is what I call a "proximity problem." Even when events are only a few miles apart, traffic can make it difficult for people to stay connected across the city. That’s why I’m so encouraged by the rise of what I think of as "intent-based gatherings" around the city: events designed with purpose, where people know they’ll find real connection and value once they arrive.

IM: Finally, what does being a "Trailblazer" mean to you?
WP: To me, trailblazing in the Houston innovation ecosystem means being willing to wander through the many different corners of the community and look for value in places we often overlook. It’s about showing up at events, community meetings, and pitch competitions — not just to participate, but to notice how each of these "nodes" in the ecosystem connects and adds value to the others.

Sometimes the trailblazer only walks a trail once: as they are discovering it. If you can help others see a newfound trail’s purpose and potential, it becomes a path others can follow more easily in the future. That’s the real work of a trailblazer: mapping connections, framing their value, and helping people recognize how those pathways strengthen the ecosystem as a whole.

In a broader sense, trailblazing is about seeing things not just as they are, but as they could be. Then taking the steps, however small, that make that vision real.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

View All Listings